Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemiaSonia Jaramillo, Richard F. Schlenk, Lucian Le Cornet et al.|Haematologica|2024Cited by 1